ZARS Pharma
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, ZARS Pharma sits in the top decile of US sponsors by registered trial count (#668 of 15,742 sponsors by registered trial count).
ZARS Pharma: 23 sponsored US clinical trials, none currently recruiting.
ZARS Pharma sponsors 23 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 19 completed. 13 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pain, with 3 trials.
Top-decile sponsor footprint
ZARS Pharma ranks in the top decile of sponsors by registered trial count (#668 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
19 of 23 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
23 total, page 1 of 1
Study Evaluating Heated Lidocaine/Tetracaine Patch in Patients With Pain Associated With Myofascial Trigger Points
NCT01106989
Study Evaluating a Heated Lidocaine and Tetracaine Topical Patch in the Treatment of Patients With Patellar Tendinopathy
NCT01111773
Study Evaluating Heated Lidocaine/Tetracaine Topical Patch in Treatment of Patients With Shoulder Impingement Syndrome
NCT01055444
Pharmacokinetic Study of Synera in Healthy Volunteers
NCT01602757
Open-Label Study Evaluating Synera® in the Treatment of Patients With Carpal Tunnel Syndrome
NCT00991068
Safety and Efficacy Study of Triamcinolone Acetonide DuraPeel to Treat Hand Dermatitis
NCT00890968
Lidocaine and Tetracaine Cream to Treat Postherpetic Neuralgia (PHN)
NCT00609323
A Phase 3 Study to Evaluate the Long-Term Safety of ThermoProfen™ in Patients With Mild to Moderate Pain Associated With Osteoarthritis of the Knee.
NCT00532038
Efficacy of ThermoProfen in Patients With Mild to Moderate Pain Associated With Osteoarthritis of the Knee
NCT00488267
Evaluate the Depth and Duration of Anesthesia
NCT00891163
Fentanyl Transdermal Patch With CHADD™ for Breakthrough Pain in Patients With Moderate to Severe Non-Malignant Pain
NCT00278824
Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Moderate to Severe Cancer Pain
NCT00126789
Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Chronic, Moderate to Severe Non-Malignant Pain
NCT00126763
Duration of Skin Numbing Effect Created by the S-Caine™ Peel
NCT00110253
S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Skin Filler Injection in the Face
NCT00110760
S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Non-Ablative Facial Laser Resurfacing in Adults
NCT00110747
S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Pulsed Dye Laser (PDL) Therapy in Adults
NCT00110773
S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Vascular Access Procedures in Children
NCT00125255
Safety Study of S-Caine Peel (Skin Numbing Cream) Before a Painful Dermatologic Procedure in Adults
NCT00107835
Transdermal Ketoprofen to Treat Mild to Moderate Osteoarthritis (OA) Pain of the Knee
NCT00108810
Safety Study of S-Caine Peel (Skin Numbing Cream) Before a Painful Dermatologic Procedure in Children
NCT00107822
Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Chronic, Moderate to Severe Osteoarthritis (OA) Pain
NCT00108771
S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Laser-Assisted Tattoo Removal in Adults
NCT00110734
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 9 |
| Phase 3 | 12 |
| Phase 4 | 1 |
Therapeutic Areas
How the ZARS Pharma archive is shaped
23 indexed studies, none listed as recruiting (0% open); 19 completed (83%).
Phase mix: 13 late (III/IV) vs 10 early (I/II) (balanced across stages).
Top condition: Pain (3 trials), 4 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
ZARS Pharma: archived-pipeline peers nationwide
Peers matched on 23 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
ZARS Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 23 archived trials
- AMAG Pharmaceuticals · 23 trials · 9% recruiting
- AtriCure · 23 trials · 22% recruiting
- Cara Therapeutics · 23 trials · 0% recruiting
- Craig L Slingluff, Jr · 23 trials · 4% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this ZARS Pharma page
23 registered trials is a research-attention snapshot, not an endorsement of ZARS Pharma or any single study.
- None of ZARS Pharma's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Pain is the condition ZARS Pharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Pain trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
ZARS Pharma pipeline card: 23 registered trials from official public datasets.Report a data error.